New information on HIV rapid turnover--what does it mean? Clearinghouse, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5023.

Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

New information on HIV rapid turnover--what does it mean? Clearinghouse, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5023.

AIDS Treat News. 1995 Jan 20;(No 215):1-4. Unique Identifier : AIDSLINE AIDS/95700104
James JS

Abstract: The results of small, rapid clinical trials, reported in January in newspapers and journals, have led to the discovery that the turnover of new virus in the body is far more rapid than previously believed. The findings suggest that the immune system might have the ability to recover if HIV reproduction could be stopped for a longer time, although the virus would not be eradicated. The new understanding of how HIV behaves in the body was made possible by new antiviral drugs and by the new blood test which measures plasma HIV RNA. The work validates the use of small, rapid trials, and emphasizes the problem of HIV developing resistance to drugs. The researchers emphasized the need to use combination treatments because the more drugs that are added, the less likely the virion will be resistant to all of them. The most important unanswered question about HIV disease may be how it progresses from early, asymptomatic infection to late-stage illness. The fear is that researchers will assume that the new understanding of HIV explains this and research could be prematurely downgraded due to the rush of enthusiasm from these new findings. The pro's and con's of the interpretations of the findings and suggestions of what should be studied are discussed. The impact of these findings will be on the strategy of research and development of new AIDS treatments.

Keywords: Antiviral Agents/THERAPEUTIC USE CD4 Lymphocyte Count/DRUG EFFECTS Human HIV/DRUG EFFECTS/*PHYSIOLOGY HIV Infections/DRUG THERAPY/IMMUNOLOGY/*VIROLOGY HIV Protease Inhibitors/THERAPEUTIC USE Pyridines/THERAPEUTIC USE RNA-Directed DNA Polymerase/ANTAGONISTS & INHIB Viremia/DRUG THERAPY/*VIROLOGY *Virus Replication NEWSLETTER ARTICLE REVIEW LITERATURE
950530
M9551015

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .